Status:
ACTIVE_NOT_RECRUITING
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
Lead Sponsor:
Children's National Research Institute
Conditions:
Growth Disorders
Eligibility:
MALE
9+ years
Phase:
PHASE2
Brief Summary
This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Be the specific subject with the a specific mutation in GHR leading to high GHBP.
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
August 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2028
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05382637
Start Date
August 26 2022
End Date
September 1 2028
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Hospital
Washington D.C., District of Columbia, United States, 20010